HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics

CAR-T Digest - August 2020

26 January 2026: HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics

HealZen Therapeutics has taken a major step onto the global stage, announcing a strategic collaboration with a U.S.-based biotech company to jointly develop Degrader–Antibody Conjugate (DAC) therapeutics, a cutting-edge modality in targeted medicine
This partnership marks the first cross-border collaboration worldwide in the DAC space, highlighting not only HealZen’s scientific capabilities but also China’s rising influence in global drug innovation and next-generation therapeutics
Under the terms of the agreement, HealZen will retain rights to the partnered DAC programs in Greater China, while securing an attractive financial package that includes an upfront payment, milestone payments, tiered sales royalties, and potential sublicense income
The deal builds on HealZen’s growing momentum in targeted protein degradation (TPD), following its BTK degrader out-licensing agreement with Johnson & Johnson announced in early 2025, further reinforcing the strength and depth of its TPD pipeline
Together, these milestones position HealZen as an emerging leader in global TPD and DAC innovation, with additional details of the collaboration expected to be disclosed at a mutually agreed time, as the partnership continues to advance